HOME >> BIOLOGY >> NEWS
New compound effectively treats fungal infections

A new mechanism to attack hard-to-treat fungal infections has been revealed by scientists from the biotech company Anacor Pharmaceuticals Inc., California, and the European Molecular Biology Laboratory (EMBL) outstation in Grenoble, France. In the current issue of Science they describe how a new compound kills fungal pathogens by blocking an enzyme crucial for their protein synthesis.

The human body is home to many different kinds of fungi. While the majority normally do not harm us, some fungi can cause unpleasant infections of skin, nails or lungs.

We have discovered a new compound that has the potential to treat common chronic nail infections caused by fungi, says Dickon Alley, researcher at Anacor Pharmaceuticals. The compound, called AN2690, kills fungi by blocking their ability to make proteins.

AN2690 interferes with an enzyme called leucyl-tRNA synthetase, which is involved in translation, one of the last steps in the process of turning a genes DNA code into a protein. The process begins when the cell makes an RNA version of the genes code, called messenger RNA. Ribosomes, the cells protein synthesis machinery, then translate the messenger RNA into protein by stitching together the amino acids in the order specified by the message. This requires the help of molecules called tRNAs, which link the code of the messenger RNA to the correct amino acid.

Leucyl-tRNA synthetase is one of a group of enzymes called aminoacyl-tRNA synthetases that attach the correct amino acid to each tRNA. Some of these enzymes have two main functional parts, or active sites: a site that links the amino acid to the tRNA, and a separate editing site that proofreads this process and removes wrongly added amino acids.

To find out how exactly AN2690 blocks leucyl-tRNA synthetase Stephen Cusack, Head of EMBL Grenoble, and his team generated crystals of the enzyme bound to tRNA in the presence of AN2690. Examining them with the high-intensity X-ray source at th
'"/>

Contact: Anna-Lynn Wegener
wegener@embl.de
49-622-138-7452
European Molecular Biology Laboratory
22-Jun-2007


Page: 1 2

Related biology news :

1. A compound from olive-pomace oil gets 80 percent slowing down of HIV spread
2. Natural compound and exercise boost memory in mice
3. Lipoic acid explored as anti-aging compound
4. Pharmaceutical compounds found in nations fresh water
5. Chinese medicinal compound stops formation of cysts in polycystic kidney disease in lab
6. EPA selects Phylonix to screen compound library in zebrafish
7. Anti-wrinkle compound causes pathological reaction in skin cells
8. Marine moss reveals clues to anticancer compound
9. New compound prevents alcoholic behavior, relapse in animals by blocking stress response
10. Light-activated compound silences nerves, may one day help epileptics
11. New compound isolated from Madagascan plant shows activity against malaria

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/27/2017)... 2017   Strategic Cyber Ventures , the industry,s ... a $3.5 million investment in  Polarity , the first ... is DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran ... this series A round of funding. This new funding ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer ... hire of Dr. Sigmund “Sig” Floyd as Vice President ? Global Business Development. ... development activities. , “Dr. Floyd’s career has spanned 30 years in the chemicals ...
(Date:3/22/2017)... CAMBRIDGE, Mass. , March 22, 2017 ... announced that it has eclipsed the 130 million covered ... Cross Blue Shield of Texas . ... stages, the Company continues to enjoy strong payor acceptance ... of its clinical programs and genetic counseling, its industry-leading ...
(Date:3/22/2017)... /PRNewswire/ - FACIT announced a seed stage investment ... start-up created by FACIT focused on developing a ... with non-dilutive capital, achieves a targeted $3.0M financing ... Propellon to accelerate the nomination of a candidate ... entering a strategic partnership for clinical trials in ...
(Date:3/22/2017)... Ca (PRWEB) , ... March 21, 2017 , ... ... clearance of biologics. To acquire information on the desired increase and/or decrease in ... biopharmaceutical industry for rapid N-glycosylation profiling of therapeutic antibodies. , To meet ...
Breaking Biology Technology:
Cached News: